Navigation Links
Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review
Date:11/22/2011

the incidence of serious adverse events generally well-balanced across the placebo and ARCALYST groups.  Injection site reactions, usually considered mild, were reported more commonly with ARCALYST than with placebo.  A third study, RE-SURGE, evaluated the safety of ARCALYST in patients who were at risk for gout flares because they were initiating or taking uric acid-lowering drug treatment.  This study showed that ARCALYST was generally well tolerated and the safety profile was consistent with that reported in the PRE-SURGE 1 and PRE-SURGE 2 studies.

About the Phase 3 ARCALYST Program in GoutIn the PRE-SURGE 1 and PRE-SURGE 2 studies, 488 patients were randomized to receive one of the following treatment regimens: ARCALYST 160 milligrams (mg) as an initial subcutaneous loading dose followed by weekly 80mg subcutaneous injections for 16 weeks, or ARCALYST 320mg as an initial subcutaneous loading dose followed by weekly 160mg subcutaneous injections for a total of 16 weeks, or subcutaneous weekly placebo injections for 16 weeks.

The North American PRE-SURGE 1 (PREventative Study against URate lowering drug-induced Gout Exacerbations) study was a double-blind, placebo-controlled study which evaluated the number of gout flares per patient over the first 16 weeks following initiation of allopurinol therapy.  Patients who received ARCALYST (rilonacept) at a weekly, self-administered, subcutaneous dose of 160mg had an 80% decrease in mean number of gout flares (p<0.0001) and patients receiving the 80mg dose had a 73% decrease compared to the placebo group (p<0.0001).

Overall in PRE-SURGE 1, the cumulative rate of infections was 17.3% in patients treated with ARCALYST 160mg, 18.8% in patients treated with ARCALYST 80mg, and 22.8% in placebo patients.  No deaths were reported in this study.

The global PRE-SURGE 2 (PREventative Study against URate-lowering
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Rockefeller University President Marc Tessier-Lavigne Elected to Regeneron Board of Directors
2. Regeneron Announces FDA Approval of EYLEA™ (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration
3. Sanofi and Regeneron Report Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia
4. Regeneron Pharmaceuticals Announces Pricing of Offering of Convertible Senior Notes due October 1, 2016
5. Regeneron Ranked by Science Magazine as the #2 Employer in the Global Biopharmaceutical Industry
6. Regeneron Announces Clinical Presentations at ASRS 2011 Annual Meeting
7. Regeneron Reports Second Quarter 2011 Financial and Operating Results
8. Sanofi and Regeneron Report Positive Phase 2b Trial Results with Sarilumab in Rheumatoid Arthritis
9. Trading in Regeneron Common Stock Halted
10. Regeneron Reports First Quarter 2011 Financial and Operating Results
11. Regeneron Announces Presentation at the Bank of America Merrill Lynch 2011 Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Cardinal Health will today name three of the nation,s ... Independent Pharmacy Best Practices Competition, during the company,s ... gatherings of independent pharmacists. The Best ... Ohio , Tennessee and ... implementing exceptionally creative methods that demonstrate how independent pharmacies ...
(Date:7/25/2014)... N.Y. and MEXICO CITY , July 25, 2014 ... that PLM, a Latin American healthcare sciences publisher, launched ... medical information on conditions such as cancer and heart ... access the most up-to-date information to deliver better patient ... is growing rapidly, with many relying on smartphones and ...
(Date:7/25/2014)...  Semler Scientific, Inc. (Nasdaq: SMLR ... that develops patented products that assist healthcare providers ... reported financial results for the second quarter and ... "The second quarter of 2014 continued to ... , M.D., chief executive officer of Semler.  "We ...
Breaking Medicine Technology:Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 2Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 3Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 4Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 5Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 6Healthcare Sciences Publisher PLM and IBM Speed Access to Medical Information to Deliver Better Patient Care with Mobile 2Healthcare Sciences Publisher PLM and IBM Speed Access to Medical Information to Deliver Better Patient Care with Mobile 3Healthcare Sciences Publisher PLM and IBM Speed Access to Medical Information to Deliver Better Patient Care with Mobile 4Semler Reports Second Quarter 2014 Financial Results 2Semler Reports Second Quarter 2014 Financial Results 3
... Oct. 29 Ferring Pharmaceuticals Inc. announces the appointment ... for Orthopaedics. Dr. Kovelman will be responsible for ... treatment for knee pain due to osteoarthritis, as well ... Kovelman is exceptionally well qualified to fill this role," ...
... NANJING, China, Oct. 29 /PRNewswire-Asia/ -- Simcere Pharmaceutical ... a leading pharmaceutical company,specializing in the development, manufacturing, ... China, today announced that it has,entered into an ... a Cayman,Islands company that, as its sole business, ...
Cached Medicine Technology:Dr. Harry Kovelman Joins Ferring Pharmaceuticals as Associate Medical Director for Orthopaedics 2Dr. Harry Kovelman Joins Ferring Pharmaceuticals as Associate Medical Director for Orthopaedics 3Simcere Pharmaceutical Group to Acquire Additional Stake in Jiangsu Yanshen Biological Technology Stock Co., Ltd. 2Simcere Pharmaceutical Group to Acquire Additional Stake in Jiangsu Yanshen Biological Technology Stock Co., Ltd. 3
(Date:7/25/2014)... CA (PRWEB) July 25, 2014 AttorneyOne.com, a ... the latest information from the FDA on Ibuprofen and ... 21, that one lot of Ibuprofen and one lot of ... due to mislabeled packaging. Oxcarbazepine is used for the ... , The reason for the recall is that ...
(Date:7/25/2014)... 2014 A new study of participants in ... are published today in Cancer , found evidence that ... who had an abnormal finding on a lung cancer screening ... life than did those who were screened and found to ... to the researchers. “We expected that participants with an abnormal ...
(Date:7/25/2014)... TX (PRWEB) July 25, 2014 ... the current state of the Galactooligosaccharides (GOS) ... a basic overview of the industry, including definitions, ... and Chinese domestic market analysis are provided with ... landscape of the market. A comparison between the ...
(Date:7/25/2014)... July 24, 2014 (HealthDay News) -- Shift workers, especially men, ... to people not on such schedules, a new study suggests. ... work on a set schedule, with shifts moving around at ... at all surprising," said one expert, Dr. Alan Manevitz, a ... "Physicians have long known that working shifts disrupts many ...
(Date:7/25/2014)... -- A new system that sent patients to designated ... victims of sudden cardiac arrest in Arizona, according to ... of Emergency Medicine . , "We knew lives ... cutting edge guidelines for post-cardiac arrest care and we ... hospitals, similar to what is done for Level 1 ...
Breaking Medicine News(10 mins):Health News:Ibuprofen and Oxcarbazepine Tablets Recalled: AttorneyOne Monitors and Keep Consumers Informed 2Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 2Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 3Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 4Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 5Health News:GOS Market (Galacto-oligosaccharides) Development in Global & China Regions Now Available at DeepResearchReports.com 2Health News:GOS Market (Galacto-oligosaccharides) Development in Global & China Regions Now Available at DeepResearchReports.com 3Health News:Study Links Shift Work to Risk for Type 2 Diabetes 2Health News:Study Links Shift Work to Risk for Type 2 Diabetes 3Health News:New EMS system in Arizona dramatically improves survival from cardiac arrest 2Health News:New EMS system in Arizona dramatically improves survival from cardiac arrest 3
... People with a mild fear of flying should take ... their breath for six to 10 seconds, just before ... Professional Association of German Psychiatrists (known by its German ... takes the mind off one's fears. ,BVDP ...
... order to prevent discrimination against the people suffering from ... on potential employees. // ,Satyam is the ... test on candidates selected for jobs in its various ... we have stopped conducting the HIV/AIDS test to protect ...
... provide free care to the poor has dropped over ... problem for America’s quickly growing number of uninsured people. ... the Center for Studying Health System Change, released on ... the mid-1990s, compared with about two-thirds now. This is ...
... down. The industry across the country is now facing a suicide ... the country, small farmers are scared due to low prices. // ... Rs 5 for one kg of chicken from Rs 1.80 and ... being forced to commit suicide. K Narayana Reddy, president, of Andhra ...
... offer a pay of nearly $500,000 to the head of ... proposal, the Queensland Opposition has described it as being extravagant ... advertised for the post of a new director for the ... $500,000-plus. This is believed to pave way for enormous ...
... person who had popularized country music in the United States ... died on // Saturday. He was 76., ,Owens' family said ... according to the website of a concert hall and restaurant he ... Aug 12, 1929, in Texas to a poor farming family, Alvis ...
Cached Medicine News:Health News:Satyam Stops Conducting HIV Tests On Employees To Prevent Discrimination 2Health News:Fewer Doctors Treating For Free 2
... practices performing routine Holter,monitoring, the ... Wizard provides a,practical, no-nonsense diagnostic ... health care,environment. This highly accurate ... a variety,of configurations at a ...
... Burdick EK-10 single-channel,electrocardiograph features ... membrane keypad. It provides ... a quick and,accurate diagnosis. ... with a built in ...
The CSV-1000ETDRS10% test face presents the standard ETDRS test at a contrast level of 10%. This test is widely used in clinical studies for the evaluation of refractive surgery and contact lenses....
... test face is used widely for screening ... LogMAR acuity from 20/10 to 20/100 and ... cycles/degree. , ,The patient can be easily ... acuity and contrast sensitivity. If a contrast ...
Medicine Products: